Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shkreli Fallout Continues: PhRMA Seems To Soften Stance On REMS Legislation

This article was originally published in The Pink Sheet Daily

Executive Summary

Brand drug representative tells Senate subcommittee there are problems with bill that would make it easier for generics to obtain samples, but did not appear interested in scrapping it.

Advertisement

Related Content

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel